In development [GID-TA10392] Expected publication date: 26 June 2020
Evidence-based recommendations on tocilizumab (RoActemra) for treating systemic juvenile idiopathic arthritis
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making
use) appeal decision 29 September 2008 TA072 Rheumatoid arthritis - anakinra 18 September 2003 TA375 Rheumatoid arthritis - adalimumab,...
This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.
This appraisal has been updated and replaced by NICE guideline CG79.
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…